CD8A and neoplasm: Importantly, CD3-TIL and CD8-TIL infiltration emerged as independent predictive factors of Vx-001’s clinical benefit in multivariate analysis adjusted for patients’ gender, age, smoking status, tumor histology and response to previous treatment.